A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks.

After May 22, compounding pharmacies can no longer make and sell semaglutide injections. They were initially allowed to because the FDA declared a shortage, but that period has ended. At Melrose ...

By Dani Blum I’ve reported on Ozempic since 2022. New research shows that semaglutide, the compound in the weight-loss drug Wegovy, could treat an increasingly common liver disease. The study ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

1 Multiple trials, including hundreds of obese/overweight women in the menopausal/postmenopausal age group, reflect weight loss of at least 5% with three months of semaglutide treatment.

1 Semaglutide 2.4 mg is not approved in the US for the treatment of MASH. ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic ...

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide ...